Cipher Pharmaceuticals Reports Record 2025 Revenue and Earnings, Eyes Future Acquisitions
CPHRF sits 60% above its 52-week low of $6.63.
Summary
Cipher Pharmaceuticals announced record full-year 2025 financial results, with total revenue increasing 51% to $50.5 million and net income surging 137% to $27.3 million. Adjusted EBITDA also grew significantly by 79% to $28.1 million, and basic EPS rose 128% to $1.07. The company generated $29.7 million in operating cash flow and made substantial debt repayments, ending the year with a cash balance exceeding its minimal outstanding long-term debt. Management highlighted exceeding goals set after the Natroba™ acquisition and expressed a strong focus on identifying and pursuing accretive acquisitions, backed by robust cash flows and $85 million in available debt financing. These strong results and clear M&A strategy are highly positive and suggest significant future growth potential.
At the time of this announcement, CPHRF was trading at $10.59 on OTC in the Life Sciences sector, with a market capitalization of approximately $268.7M. The 52-week trading range was $6.63 to $12.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.